Private-equity firms and other investors are funding late-stage clinical trials, shouldering the risk for pharmaceutical companies like Pfizer in exchange for a share of the upside if a drug succeeds.
from WSJ.com: US Business http://ift.tt/2pkzIN0
via IFTTT
No comments:
Post a Comment